1 Magnificent Dividend Growth Stock That Could Soar 20% in 2025, According to a Couple of Wall Street Analysts
On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...
TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...
TD Cowen's investment themes for 2025: Spotting opportunities and risks
Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...